Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Johnson and Johnson
Mallinckrodt
Moodys
Harvard Business School

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,308,276

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,308,276
Title:Combination therapy for treatment of cancer
Abstract: The present invention relates to methods and compositions for the treatment of cancer. Some embodiments include methods of treating cancer comprising administering a chemotherapeutic agent associated with albumin, administering a second chemotherapeutic agent; and administering a third chemotherapeutic agent.
Inventor(s): Khong; Hung T. (Mobile, AL)
Assignee: UNIVERSITY OF SOUTH ALABAMA (Mobile, AL)
Application Number:14/117,832
Patent Claims:1. A method of treating a HER2 negative breast cancer in a subject in need thereof comprising: administering a chemotherapeutic agent associated with or bound to albumin, wherein the chemotherapeutic agent associated with or bound to albumin is selected from the group consisting of paclitaxel, docetaxel, and rapamycin; administering a topoisomerase inhibitor; and administering an alkylating agent, wherein the chemotherapeutic agent associated with or bound to albumin, the topoisomerase inhibitor, and the alkylating agent are administered on the same day.

2. The method of claim 1, wherein administration of the chemotherapeutic agent associated with or bound to albumin is repeated.

3. The method of claim 1, wherein administration of the topoisomerase inhibitor and the agent is not repeated.

4. The method of claim 1, wherein the chemotherapeutic agent associated with or bound to albumin comprises nab-paclitaxel.

5. The method of claim 4, wherein the administered dose of nab-paclitaxel is between about 50 mg/m.sup.2 and about 200 mg/m.sup.2.

6. The method of claim 4, wherein the administered dose of nab-paclitaxel is selected from the group consisting of 100 mg/m.sup.2 and 150 mg/m.sup.2.

7. The method of claim 1, wherein the topoisomerase inhibitor is doxorubicin.

8. The method of claim 1, wherein the alkylating agent is cyclophosphamide.

9. The method of claim 1, wherein the chemotherapeutic agent associated with or bound to albumin is administered on days 1 and 8.

10. The method of claim 2, wherein the chemotherapeutic agent associated with or bound to albumin is administered at an interval of at least about 5 days.

11. The method of claim 2, wherein the administration of the chemotherapeutic agent associated with or bound to albumin is repeated at least 2 times.

12. The method of claim 2, wherein the administration of the chemotherapeutic agent associated with or bound to albumin is repeated at least 5 times.

13. The method of claim 3, wherein administration of the chemotherapeutic agent associated with or bound to albumin is repeated.

14. The method of claim 13, wherein administration of the chemotherapeutic agent associated with or bound to albumin is repeated at least 2 times.

15. The method of claim 13, wherein administration of the chemotherapeutic agent associated with or bound to albumin is repeated at least 5 times.

16. The method of claim 13, wherein administration of the chemotherapeutic agent associated with or bound to albumin comprises is repeated with an interval of at least about 5 days.

17. The method of claim 4, wherein at least about 100 mg/m.sup.2 nab-paclitaxel is administered on days 1 and 8, at least about 50 mg/m.sup.2 doxorubicin is administered on day 1, and at least about 500 mg/m.sup.2 cyclophosphamide is administered on day 1.

18. The method of claim 17, further comprising administering pegfilgrastim on day 9.

19. The method of claim 1, wherein the breast cancer is triple negative breast cancer.

20. The method of claim 1, wherein the chemotherapeutic agent associated with or bound to albumin is nab-paclitaxel, the topoisomerase inhibitor is doxorubicin, and the alkylating agent is cyclophosphamide.

21. The method of claim 1, wherein the alkylating agent is selected from the group consisting of mechlorethamine, cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, melphalan, prednimustine, bendamustine, uramustine, carmustine, lomustine, fotemustine, nimustine, ranimustine, streptozocin, busulfan, mannosulfan, treosulfan, carboquone, N,N'N'-triethylenethiophosphoramide (thioTEPA), triaziquone, and triethylenemelamine.

22. The method of claim 1, wherein the topoisomerase inhibitor is selected from the group consisting of camptothecin, topotecan, irinotecan, rubitecan, belotecan, etoposide, teniposide, aclarubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, amrubicin, pirarubicin, valrubicin, zorubicin, mitoxantrone, and pixantrone.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
McKinsey
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.